The notch signaling pathway in esophageal adenocarcinoma

Cellular and Molecular Biology

Volumn 61, Issue 6, 2015, Pages 24-32

  Wang, Zhiqiang ^a   Chen, J ^b   Capobianco, A J ^a,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Barrett; s esophagus (BE); Cancer stem cells (CSCs); Esophageal adenocarcinoma (EAC); Gamma secretase inhibitor (GSI); Notch signaling

Indexed keywords

NOTCH RECEPTOR; SECRETASE;

ARTICLE; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STEM CELL; CARCINOGENICITY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; METABOLISM;

ADENOCARCINOMA; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84962167853     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.14715/cmb/2015.61.6.5     Document Type: Article

References (122)

1. Parkin, D.M., F. Bray, J. Ferlay, and P. Pisani, Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55(2): p. 74-108. DOI: 10.3322/canjclin.55.2.74.
2. Pisani, P., D.M. Parkin, F. Bray, and J. Ferlay, Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer, 1999. 83(1): p. 18-29. DOI: 10.1002/(SICI)1097-0215(19991210)83:6<870::AID-IJC35>3.0.CO;2-9.
3. Brown, L.M., S.S. Devesa, and W.H. Chow, Incidence of ade-nocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst, 2008. 100(16): p. 1184-7. DOI: 10.1093/jnci/djn211.
4. Blot, W.J., S.S. Devesa, R.W. Kneller, and J.F. Fraumeni, Jr., Rising incidence of adenocarcinoma of the esophagus and gas-tric cardia. JAMA, 1991. 265(10): p. 1287-9. DOI: 10.1001/jama.1991.03460100089030.
5. Lassen, A., J. Hallas, and O.B. de Muckadell, Esophagitis: inci-dence and risk of esophageal adenocarcinoma--a population-based cohort study. Am J Gastroenterol, 2006. 101(6): p. 1193-9. DOI: 10.1111/j.1572-0241.2006.00550.x.
6. Stavrou, E.P., H.J. McElroy, D.F. Baker, G. Smith, and J.F. Bi-shop, Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972-2005. Med J Aust, 2009. 191(6): p. 310-4.
7. Smith, K.J., S.M. O'Brien, B.M. Smithers, D.C. Gotley, P.M. Webb, A.C. Green, and D.C. Whiteman, Interactions among smo-king, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev, 2005. 14(11 Pt 1): p. 2481-6. DOI: 10.1158/1055-9965.EPI-05-0370.
8. Smith, K.J., S.M. O'Brien, A.C. Green, P.M. Webb, D.C. Whi-teman, and H. Study of Digestive, Current and past smoking signi-ficantly increase risk for Barrett's esophagus. Clin Gastroenterol Hepatol, 2009. 7(8): p. 840-8. DOI: 10.1016/j.cgh.2009.04.018.
9. Cook, M.B., F. Kamangar, D.C. Whiteman, N.D. Freedman, M.D. Gammon, L. Bernstein, L.M. Brown, H.A. Risch, W. Ye, L. Sharp, N. Pandeya, P.M. Webb, A.H. Wu, M.H. Ward, C. Giffen, A.G. Casson, C.C. Abnet, L.J. Murray, D.A. Corley, O. Nyren, T.L. Vaughan, and W.H. Chow, Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst, 2010. 102(17): p. 1344-53. DOI: 10.1093/jnci/djq289.
10. Pandeya, N., P.M. Webb, S. Sadeghi, A.C. Green, D.C. White-man, and S. Australian Cancer, Gastro-oesophageal reflux symp-toms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut, 2010. 59(1): p. 31-8. DOI: 10.1136/gut.2009.190827.
11. Paulson, T.G. and B.J. Reid, Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell, 2004. 6(1): p. 11-6. DOI: 10.1016/j.ccr.2004.06.021.
12. Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2012. CA Cancer J Clin, 2012. 62(1): p. 10-29. DOI: 10.3322/caac.20138.
13. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA Cancer J Clin, 2015. 65(1): p. 5-29. DOI: 10.3322/caac.21254.
14. Artavanis-Tsakonas, S., K. Matsuno, and M.E. Fortini, Notch signaling. Science, 1995. 268(5208): p. 225-32. DOI: 10.1126/science.7716513.
15. Ranganathan, P., K.L. Weaver, and A.J. Capobianco, Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer, 2011. 11(5): p. 338-51. DOI: 10.1038/nrc3035.
16. Capobianco, A.J., P. Zagouras, C.M. Blaumueller, S. Artavanis-Tsakonas, and J.M. Bishop, Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol Cell Biol, 1997. 17(11): p. 6265-73.
17. Baron, M., An overview of the Notch signalling pathway. Semin Cell Dev Biol, 2003. 14(2): p. 113-9. DOI: 10.1016/S1084-9521(02)00179-9.
18. De Strooper, B., W. Annaert, P. Cupers, P. Saftig, K. Craessaerts, J.S. Mumm, E.H. Schroeter, V. Schrijvers, M.S. Wolfe, W.J. Ray, A. Goate, and R. Kopan, A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature, 1999. 398(6727): p. 518-22. DOI: 10.1038/19083.
19. Mumm, J.S., E.H. Schroeter, M.T. Saxena, A. Griesemer, X. Tian, D.J. Pan, W.J. Ray, and R. Kopan, A ligand-induced extracel-lular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell, 2000. 5(2): p. 197-206. DOI: 10.1016/S1097-2765(00)80416-5.
20. Milano, J., J. McKay, C. Dagenais, L. Foster-Brown, F. Pognan, R. Gadient, R.T. Jacobs, A. Zacco, B. Greenberg, and P.J. Ciac-cio, Modulation of notch processing by gamma-secretase inhibi-tors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci, 2004. 82(1): p. 341-58. DOI: 10.1093/toxsci/kfh254.
21. Searfoss, G.H., W.H. Jordan, D.O. Calligaro, E.J. Galbreath, L.M. Schirtzinger, B.R. Berridge, H. Gao, M.A. Higgins, P.C. May, and T.P. Ryan, Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem, 2003. 278(46): p. 46107-16. DOI: 10.1074/jbc.M307757200.
22. van Es, J.H., M.E. van Gijn, O. Riccio, M. van den Born, M. Vooijs, H. Begthel, M. Cozijnsen, S. Robine, D.J. Winton, F. Radtke, and H. Clevers, Notch/gamma-secretase inhibition turns prolifera-tive cells in intestinal crypts and adenomas into goblet cells. Nature, 2005. 435(7044): p. 959-63. DOI: 10.1038/nature03659.
23. Wong, G.T., D. Manfra, F.M. Poulet, Q. Zhang, H. Josien, T. Bara, L. Engstrom, M. Pinzon-Ortiz, J.S. Fine, H.J. Lee, L. Zhang, G.A. Higgins, and E.M. Parker, Chronic treatment with the gam-ma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentia-tion. J Biol Chem, 2004. 279(13): p. 12876-82. DOI: 10.1074/jbc.M311652200.
24. Ellisen, L.W., J. Bird, D.C. West, A.L. Soreng, T.C. Reynolds, S.D. Smith, and J. Sklar, TAN-1, the human homolog of the Dro-sophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 1991. 66(4): p. 649-61. DOI: 10.1016/0092-8674(91)90111-B.
25. Demarest, R.M., N. Dahmane, and A.J. Capobianco, Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia. Blood, 2011. 117(10): p. 2901-9. DOI: 10.1182/blood-2010-05-286351.
26. Weng, A.P., A.A. Ferrando, W. Lee, J.P.t. Morris, L.B. Silver-man, C. Sanchez-Irizarry, S.C. Blacklow, A.T. Look, and J.C. As-ter, Activating mutations of NOTCH1 in human T cell acute lym-phoblastic leukemia. Science, 2004. 306(5694): p. 269-71. DOI: 10.1126/science.1102160.
27. Pinnix, C.C., J.T. Lee, Z.J. Liu, R. McDaid, K. Balint, L.J. Beverly, P.A. Brafford, M. Xiao, B. Himes, S.E. Zabierowski, Y. Yashiro-Ohtani, K.L. Nathanson, A. Bengston, P.M. Pollock, A.T. Weeraratna, B.J. Nickoloff, W.S. Pear, A.J. Capobianco, and M. Herlyn, Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res,2009. 69(13): p. 5312-20. DOI: 10.1158/0008-5472.CAN-08-3767.
28. Mittal, S., D. Subramanyam, D. Dey, R.V. Kumar, and A. Ran-garajan, Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer, 2009. 8: p. 128. DOI: 10.1186/1476-4598-8-128.
29. Reedijk, M., S. Odorcic, H. Zhang, R. Chetty, C. Tennert, B.C. Dickson, G. Lockwood, S. Gallinger, and S.E. Egan, Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol, 2008. 33(6): p. 1223-9. DOI: 10.3892/ijo_00000112.
30. Mullendore, M.E., J.B. Koorstra, Y.M. Li, G.J. Offerhaus, X. Fan, C.M. Henderson, W. Matsui, C.G. Eberhart, A. Maitra, and G. Feldmann, Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res, 2009. 15(7): p. 2291-301. DOI: 10.1158/1078-0432.CCR-08-2004.
31. Westhoff, B., I.N. Colaluca, G. D'Ario, M. Donzelli, D. Tosoni, S. Volorio, G. Pelosi, L. Spaggiari, G. Mazzarol, G. Viale, S. Pece, and P.P. Di Fiore, Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A, 2009. 106(52): p. 22293-8. DOI: 10.1073/pnas.0907781106.
32. Sun, P., S. Xia, B. Lal, C.G. Eberhart, A. Quinones-Hinojosa, J. Maciaczyk, W. Matsui, F. Dimeco, S.M. Piccirillo, A.L. Vescovi, and J. Laterra, DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells, 2009. 27(7): p. 1473-86. DOI: 10.1002/stem.89.
33. Lee, C.W., C.M. Raskett, I. Prudovsky, and D.C. Altieri, Mole- Stan- cular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res, 2008. 68(13): p. 5273-81. DOI: 10.1158/0008-5472.CAN-07-6673.
34. Meng, R.D., C.C. Shelton, Y.M. Li, L.X. Qin, D. Notterman, P.B. Paty, and G.K. Schwartz, gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res, 2009. 69(2): p. 573-82. DOI: 10.1158/0008-5472.CAN-08-2088.
35. Mendelson, J., S. Song, Y. Li, D.M. Maru, B. Mishra, M. Davila, W.L. Hofstetter, and L. Mishra, Dysfunctional transforming growth factor-beta signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. Cancer, 2011. 117(16): p. 3691-702. DOI: 10.1002/cncr.25861.
36. Farnie, G. and R.B. Clarke, Mammary stem cells and breast can-cer--role of Notch signalling. Stem Cell Rev, 2007. 3(2): p. 169-75. DOI: 10.1007/s12015-007-0023-5.
37. Song, S., D.M. Maru, J.A. Ajani, C.H. Chan, S. Honjo, H.K. Lin, A. Correa, W.L. Hofstetter, M. Davila, J. Stroehlein, and L. Mishra, Loss of TGF-beta adaptor beta2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res, 2013. 73(7): p. 2159-69. DOI: 10.1158/0008-5472.CAN-12-1962.
38. Wang, Z., T.G. Da Silva, K. Jin, X. Han, P. Ranganathan, X. Zhu, A. Sanchez-Mejias, F. Bai, B. Li, D.L. Fei, K. Weaver, R.V. Carpio, A.E. Moscowitz, V.P. Koshenkov, L. Sanchez, L. Sparling, X.H. Pei, D. Franceschi, A. Ribeiro, D.J. Robbins, A.S. Livingstone, and A.J. Capobianco, Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res, 2014. 74(21): p. 6364-74. DOI: 10.1158/0008-5472.CAN-14-2051.
39. Menke, V., J.H. van Es, W. de Lau, M. van den Born, E.J. Kui-pers, P.D. Siersema, R.W. de Bruin, J.G. Kusters, and H. Clevers, Conversion of metaplastic Barrett's epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Model Mech, 2010. 3(1-2): p. 104-10. DOI: 10.1242/dmm.003012.
40. Moghbeli, M., M.M. Forghanifard, A. Sadrizadeh, H.M. Mo-zaffari, E. Golmakani, and M.R. Abbaszadegan, Role of Msi1 and MAML1 in Regulation of Notch Signaling Pathway in Patients with Esophageal Squamous Cell Carcinoma. J Gastrointest Cancer, 2015. DOI: 10.1007/s12029-015-9753-9.
41. Li, W., Y. Zhou, Y. Su, Y. Ouyang, X. Xie, Y. Wu, C. Mao, and D. Chen, IL-23 promotes invasion of esophageal squamous cell car-cinoma cells by activating DLL4/Notch1 signaling pathway. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2015. 31(6): p. 812-5.
42. Liu, C., P. Duan, B. Li, C. Huang, Y. Jing, and W. Yan, miR-29a activates Hes1 by targeting Nfia in esophageal carcinoma cell line TE-1. Oncol Lett, 2015. 9(1): p. 96-102. DOI: 10.3892/ol.2014.2678.
43. Forghanifard, M.M., S. Taleb, and M.R. Abbaszadegan, Notch Signaling Target Genes are Directly Correlated to Esophageal Squa-mous Cell Carcinoma Tumorigenesis. Pathol Oncol Res, 2015. 21(2): p. 463-7. DOI: 10.1007/s12253-014-9849-8.
44. Taleb, S., M.R. Abbaszadegan, M. Moghbeli, N.H. Roudbari, and M.M. Forghanifard, HES1 as an independent prognostic mar-ker in esophageal squamous cell carcinoma. J Gastrointest Cancer, 2014. 45(4): p. 466-71. DOI: 10.1007/s12029-014-9648-1.
45. Ogawa, R., H. Ishiguro, M. Kimura, H. Funahashi, T. Wakasu-gi, T. Ando, M. Shiozaki, and H. Takeyama, NOTCH1 expression predicts patient prognosis in esophageal squamous cell cancer. Eur Surg Res, 2013. 51(3-4): p. 101-7. DOI: 10.1159/000355674.
46. Liu, J., H. Fan, Y. Ma, D. Liang, R. Huang, J. Wang, F. Zhou, Q. Kan, L. Ming, H. Li, K.E. Giercksky, J.M. Nesland, and Z. Suo, Notch1 is a 5-fluorouracil resistant and poor survival marker in hu-man esophagus squamous cell carcinomas. PLoS One, 2013. 8(2): p. e56141. DOI: 10.1371/journal.pone.0056141.
47. Subramaniam, D., S. Ponnurangam, P. Ramamoorthy, D. Stan- ding, R.J. Battafarano, S. Anant, and P. Sharma, Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One, 2012. 7(2): p. e30590. DOI: 10.1371/journal.pone.0030590.
48. Harrison, H., G. Farnie, S.J. Howell, R.E. Rock, S. Stylianou, K.R. Brennan, N.J. Bundred, and R.B. Clarke, Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res, 2010. 70(2): p. 709-18. DOI: 10.1158/0008-5472.CAN-09-1681.
49. Chen, J., N. Imanaka, J. Chen, and J.D. Griffin, Hypoxia po-tentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer, 2010. 102(2): p. 351-60. DOI: 10.1038/sj.bjc.6605486.
50. Nam, D.H., H.M. Jeon, S. Kim, M.H. Kim, Y.J. Lee, M.S. Lee, H. Kim, K.M. Joo, D.S. Lee, J.E. Price, S.I. Bang, and W.Y. Park, Activation of notch signaling in a xenograft model of brain metasta-sis. Clin Cancer Res, 2008. 14(13): p. 4059-66. DOI: 10.1158/1078-0432.CCR-07-4039.
51. Florena, A.M., C. Tripodo, C. Guarnotta, S. Ingrao, R. Porcasi, A. Martorana, G. Lo Bosco, D. Cabibi, and V. Franco, Associa-tions between Notch-2, Akt-1 and HER2/neu expression in inva-sive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients. Pathobiology, 2007. 74(6): p. 317-22. DOI: 10.1159/000110024.
52. Ramdass, B., T.T. Maliekal, S. Lakshmi, M. Rehman, P. Rema, P. Nair, G. Mukherjee, B.K. Reddy, S. Krishna, and M. Radhakrishna Pillai, Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol, 2007. 104(2): p. 352-61. DOI: 10.1016/j.ygyno.2006.08.054.
53. Thorland, E.C., S.L. Myers, B.S. Gostout, and D.I. Smith, Com-mon fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene, 2003. 22(8): p. 1225-37. DOI: 10.1038/sj.onc.1206170.
54. Veeraraghavalu, K., M. Pett, R.V. Kumar, P. Nair, A. Rangarajan, M.A. Stanley, and S. Krishna, Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in JAGGED1 and manic fringe expression linked to notch activation. J Virol, 2004. 78(16): p. 8687-700. DOI: 10.1128/JVI.78.16.8687-8700.2004.
55. Song, L.L., Y. Peng, J. Yun, P. Rizzo, V. Chaturvedi, S. Wei-jzen, W.M. Kast, P.J. Stone, L. Santos, A. Loredo, U. Lendahl, G. Sonenshein, B. Osborne, J.Z. Qin, A. Pannuti, B.J. Nickoloff, and L. Miele, Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene, 2008. 27(44): p. 5833-44. DOI: 10.1038/onc.2008.190.
56. Miyaki, M., T. Yamaguchi, T. Iijima, K. Takahashi, H. Matsu-moto, and T. Mori, Somatic mutations of the CDC4 (FBXW7) gene in hereditary colorectal tumors. Oncology, 2009. 76(6): p. 430-4. DOI: 10.1159/000217811.
57. Rodilla, V., A. Villanueva, A. Obrador-Hevia, A. Robert-Mo-reno, V. Fernandez-Majada, A. Grilli, N. Lopez-Bigas, N. Bellora, M.M. Alba, F. Torres, M. Dunach, X. Sanjuan, S. Gonzalez, T. Gri-dley, G. Capella, A. Bigas, and L. Espinosa, Jagged1 is the patho-logical link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A, 2009. 106(15): p. 6315-20. DOI: 10.1073/pnas.0813221106.
58. Fre, S., S.K. Pallavi, M. Huyghe, M. Lae, K.P. Janssen, S. Ro-bine, S. Artavanis-Tsakonas, and D. Louvard, Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the in-testine. Proc Natl Acad Sci U S A, 2009. 106(15): p. 6309-14. DOI: 10.1073/pnas.0900427106.
59. Akiyoshi, T., M. Nakamura, K. Yanai, S. Nagai, J. Wada, K. Koga, H. Nakashima, N. Sato, M. Tanaka, and M. Katano, Gam-ma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology, 2008. 134(1): p. 131-44. DOI: 10.1053/j.gastro.2007.10.008.
60. Gu, F., Y. Ma, Z. Zhang, J. Zhao, H. Kobayashi, L. Zhang, and L. Fu, Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep, 2010. 23(3): p. 671-6. DOI: 10.3892/or_00000683.
61. Sriuranpong, V., M.W. Borges, R.K. Ravi, D.R. Arnold, B.D. Nelkin, S.B. Baylin, and D.W. Ball, Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res, 2001. 61(7): p. 3200-5.
62. Haruki, N., K.S. Kawaguchi, S. Eichenberger, P.P. Massion, S. Olson, A. Gonzalez, D.P. Carbone, and T.P. Dang, Dominant-ne-gative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res, 2005. 65(9): p. 3555-61. DOI: 10.1158/0008-5472.CAN-04-3132.
63. Konishi, J., K.S. Kawaguchi, H. Vo, N. Haruki, A. Gonzalez, D.P. Carbone, and T.P. Dang, Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res, 2007. 67(17): p. 8051-7. DOI: 10.1158/0008-5472.CAN-07-1022.
64. Lin, L., R. Mernaugh, F. Yi, D. Blum, D.P. Carbone, and T.P. Dang, Targeting specific regions of the Notch3 ligand-binding do-main induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res, 2010. 70(2): p. 632-8. DOI: 10.1158/0008-5472.CAN-09-3293.
65. Fan, X., I. Mikolaenko, I. Elhassan, X. Ni, Y. Wang, D. Ball, D.J. Brat, A. Perry, and C.G. Eberhart, Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res, 2004. 64(21): p. 7787-93. DOI: 10.1158/0008-5472.CAN-04-1446.
66. Hallahan, A.R., J.I. Pritchard, S. Hansen, M. Benson, J. Stoeck, B.A. Hatton, T.L. Russell, R.G. Ellenbogen, I.D. Bernstein, P.A. Beachy, and J.M. Olson, The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedge-hog-induced medulloblastomas. Cancer Res, 2004. 64(21): p. 7794-800. DOI: 10.1158/0008-5472.CAN-04-1813.
67. Hoek, K., D.L. Rimm, K.R. Williams, H. Zhao, S. Ariyan, A. Lin, H.M. Kluger, A.J. Berger, E. Cheng, E.S. Trombetta, T. Wu, M. Niinobe, K. Yoshikawa, G.E. Hannigan, and R. Halaban, Expression profiling reveals novel pathways in the transformation of melano-cytes to melanomas. Cancer Res, 2004. 64(15): p. 5270-82. DOI: 10.1158/0008-5472.CAN-04-0731.
68. Liu, Z.J., M. Xiao, K. Balint, K.S. Smalley, P. Brafford, R. Qiu, C.C. Pinnix, X. Li, and M. Herlyn, Notch1 signaling promotes pri-mary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regula-ting N-cadherin expression. Cancer Res, 2006. 66(8): p. 4182-90. DOI: 10.1158/0008-5472.CAN-05-3589.
69. Balint, K., M. Xiao, C.C. Pinnix, A. Soma, I. Veres, I. Juhasz, E.J. Brown, A.J. Capobianco, M. Herlyn, and Z.J. Liu, Activation of Notch1 signaling is required for beta-catenin-mediated human pri-mary melanoma progression. J Clin Invest, 2005. 115(11): p. 3166-76. DOI: 10.1172/JCI25001.
70. Plentz, R., J.S. Park, A.D. Rhim, D. Abravanel, A.F. Hezel, S.V. Sharma, S. Gurumurthy, V. Deshpande, C. Kenific, J. Settleman, P.K. Majumder, B.Z. Stanger, and N. Bardeesy, Inhibition of gam-ma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology, 2009. 136(5): p. 1741-9 e6. DOI: 10.1053/j.gastro.2009.01.008.
71. Sawey, E.T., J.A. Johnson, and H.C. Crawford, Matrix metallo-proteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc Natl Acad Sci U S A, 2007. 104(49): p. 19327-32. DOI: 10.1073/pnas.0705953104.
72. Kimura, K., K. Satoh, A. Kanno, S. Hamada, M. Hirota, M. En-doh, A. Masamune, and T. Shimosegawa, Activation of Notch signa-ling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci, 2007. 98(2): p. 155-62. DOI: 10.1111/j.1349-7006.2006.00369.x.
73. De La, O.J., L.L. Emerson, J.L. Goodman, S.C. Froebe, B.E. Illum, A.B. Curtis, and L.C. Murtaugh, Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A, 2008. 105(48): p. 18907-12. DOI: 10.1073/pnas.0810111105.
74. Doucas, H., C.D. Mann, C.D. Sutton, G. Garcea, C.P. Neal, D.P. Berry, and M.M. Manson, Expression of nuclear Notch3 in pancrea-tic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J Surg Oncol, 2008. 97(1): p. 63-8. DOI: 10.1002/jso.20894.
75. Wang, Z., S. Banerjee, Y. Li, K.M. Rahman, Y. Zhang, and F.H. Sarkar, Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res, 2006. 66(5): p. 2778-84. DOI: 10.1158/0008-5472.CAN-05-4281.
76. Yao, J. and C. Qian, Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol, 2010. 27(3): p. 1017-22. DOI: 10.1007/s12032-009-9326-5.
77. Ristorcelli, E., E. Beraud, S. Mathieu, D. Lombardo, and A. Verine, Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. Int J Cancer, 2009. 125(5): p. 1016-26. DOI: 10.1002/ijc.24375.
78. Wang, Z., A.S. Azmi, A. Ahmad, S. Banerjee, S. Wang, F.H. Sarkar, and R.M. Mohammad, TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic can-cer: involvement of Notch-1 signaling pathway. Cancer Res, 2009. 69(7): p. 2757-65. DOI: 10.1158/0008-5472.CAN-08-3060.
79. Wang, Z., Y. Li, D. Kong, S. Banerjee, A. Ahmad, A.S. Azmi, S. Ali, J.L. Abbruzzese, G.E. Gallick, and F.H. Sarkar, Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res, 2009. 69(6): p. 2400-7. DOI: 10.1158/0008-5472.CAN-08-4312.
80. Panelos, J., F. Tarantini, M. Paglierani, C. Di Serio, V. Maio, S. Pellerito, N. Pimpinelli, M. Santucci, and D. Massi, Photoexposition discriminates Notch 1 expression in human cutaneous squamous cell carcinoma. Mod Pathol, 2008. 21(3): p. 316-25. DOI: 10.1038/mod-pathol.3801007.
81. Proweller, A., L. Tu, J.J. Lepore, L. Cheng, M.M. Lu, J. Seykora, S.E. Millar, W.S. Pear, and M.S. Parmacek, Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res, 2006. 66(15): p. 7438-44. DOI: 10.1158/0008-5472.CAN-06-0793.
82. Katoh, M. and M. Katoh, Notch signaling in gastrointestinal tract (review). Int J Oncol, 2007. 30(1): p. 247-51. DOI: 10.3892/ijo.30.1.247.
83. Horwhat, J.D., D. Baroni, C. Maydonovitch, E. Osgard, E. Orm-seth, E. Rueda-Pedraza, H.J. Lee, W.K. Hirota, and R.K. Wong, Normalization of intestinal metaplasia in the esophagus and esopha-gogastric junction: incidence and clinical data. Am J Gastroenterol, 2007. 102(3): p. 497-506. DOI: 10.1111/j.1572-0241.2006.00994.x.
84. Pera, M., Trends in incidence and prevalence of specialized in-testinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg, 2003. 27(9): p. 999-1008; discussion 1006-8. DOI: 10.1007/s00268-003-7052-2.
85. Chen, X., K. Jiang, Z. Fan, Z. Liu, P. Zhang, L. Zheng, N. Peng, J. Tong, and G. Ji, Aberrant expression of Wnt and Notch signal pathways in Barrett's esophagus. Clin Res Hepatol Gastroenterol, 2012. 36(5): p. 473-83. DOI: 10.1016/j.clinre.2012.06.001.
86. Tamagawa, Y., N. Ishimura, G. Uno, T. Yuki, H. Kazumori, S. Ishihara, Y. Amano, and Y. Kinoshita, Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus. Lab Invest, 2012. 92(6): p. 896-909. DOI: 10.1038/labinvest.2012.56.
87. Vega, M.E., V. Giroux, M. Natsuizaka, M. Liu, A.J. Klein-Szan-to, D.B. Stairs, H. Nakagawa, K.K. Wang, T.C. Wang, J.P. Lynch, and A.K. Rustgi, Inhibition of Notch signaling enhances transdif-ferentiation of the esophageal squamous epithelium towards a Bar-rett's-like metaplasia via KLF4. Cell Cycle, 2014. 13(24): p. 3857-66. DOI: 10.4161/15384101.2014.972875.
88. Shaheen, N.J., M.A. Crosby, E.M. Bozymski, and R.S. Sandler, Is there publication bias in the reporting of cancer risk in Bar-rett's esophagus? Gastroenterology, 2000. 119(2): p. 333-8. DOI: 10.1053/gast.2000.9302.
89. Aster, J., W. Pear, R. Hasserjian, H. Erba, F. Davi, B. Luo, M. Scott, D. Baltimore, and J. Sklar, Functional analysis of the TAN-1 gene, a human homolog of Drosophila notch. Cold Spring Harb Symp Quant Biol, 1994. 59: p. 125-36. DOI: 10.1101/SQB.1994.059.01.016.
90. Kopan, R. and M.X. Ilagan, The canonical Notch signaling pa-thway: unfolding the activation mechanism. Cell, 2009. 137(2): p. 216-33. DOI: 10.1016/j.cell.2009.03.045.
91. Quante, M., G. Bhagat, J.A. Abrams, F. Marache, P. Good, M.D. Lee, Y. Lee, R. Friedman, S. Asfaha, Z. Dubeykovskaya, U. Mah-mood, J.L. Figueiredo, J. Kitajewski, C. Shawber, C.J. Lightdale, A.K. Rustgi, and T.C. Wang, Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell, 2012. 21(1): p. 36-51. DOI: 10.1016/j.ccr.2011.12.004.
92. Dean, M., T. Fojo, and S. Bates, Tumour stem cells and drug resistance. Nat Rev Cancer, 2005. 5(4): p. 275-84. DOI: 10.1038/nrc1590.
93. Yu, F., H. Yao, P. Zhu, X. Zhang, Q. Pan, C. Gong, Y. Huang, X. Hu, F. Su, J. Lieberman, and E. Song, let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 2007. 131(6): p. 1109-23. DOI: 10.1016/j.cell.2007.10.054.
94. Kucia, M., R. Reca, K. Miekus, J. Wanzeck, W. Wojakowski, A. Janowska-Wieczorek, J. Ratajczak, and M.Z. Ratajczak, Traffic-king of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells, 2005. 23(7): p. 879-94. DOI: 10.1634/stemcells.2004-0342.
95. Hermann, P.C., S.L. Huber, T. Herrler, A. Aicher, J.W. Ellwart, M. Guba, C.J. Bruns, and C. Heeschen, Distinct populations of can-cer stem cells determine tumor growth and metastatic activity in hu-man pancreatic cancer. Cell Stem Cell, 2007. 1(3): p. 313-23. DOI: 10.1016/j.stem.2007.06.002.
96. Patrawala, L., T. Calhoun, R. Schneider-Broussard, J. Zhou, K. Claypool, and D.G. Tang, Side population is enriched in tumorige-nic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res, 2005. 65(14): p. 6207-19. DOI: 10.1158/0008-5472.CAN-05-0592.
97. Houghton, J., C. Stoicov, S. Nomura, A.B. Rogers, J. Carlson, H. Li, X. Cai, J.G. Fox, J.R. Goldenring, and T.C. Wang, Gastric cancer originating from bone marrow-derived cells. Science, 2004. 306(5701): p. 1568-71. DOI: 10.1126/science.1099513.
98. Huang, D., Q. Gao, L. Guo, C. Zhang, W. Jiang, H. Li, J. Wang, X. Han, Y. Shi, and S.H. Lu, Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev, 2009. 18(3): p. 465-73. DOI: 10.1089/scd.2008.0033.
99. Grotenhuis, B.A., W.N. Dinjens, B.P. Wijnhoven, P. Sonneveld, A. Sacchetti, P.F. Franken, H. van Dekken, H.W. Tilanus, J.J. van Lanschot, and R. Fodde, Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J Pathol, 2010. 221(4): p. 379-89. DOI: 10.1002/path.2733.
100. Kanwar, S.S., Y. Yu, J. Nautiyal, B.B. Patel, and A.P. Majumdar, The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer, 2010. 9: p. 212. DOI: 10.1186/1476-4598-9-212.
101. Visvader, J.E. and G.J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 2008. 8(10): p. 755-68. DOI: 10.1038/nrc2499.
102. Katoh, Y. and M. Katoh, Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol, 2009. 35(1): p. 187-92. DOI: 10.3892/ijo_00000328.
103. Schreck, K.C., P. Taylor, L. Marchionni, V. Gopalakrishnan, E.E. Bar, N. Gaiano, and C.G. Eberhart, The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a po-tential mechanism of therapeutic resistance. Clin Cancer Res, 2010. 16(24): p. 6060-70. DOI: 10.1158/1078-0432.CCR-10-1624.
104. Yang, L., L.S. Wang, X.L. Chen, Z. Gatalica, S. Qiu, Z. Liu, G. Stoner, H. Zhang, H. Weiss, and J. Xie, Hedgehog signaling activa-tion in the development of squamous cell carcinoma and adenocar-cinoma of esophagus. Int J Biochem Mol Biol, 2012. 3(1): p. 46-57.
105. Clement, G., D.M. Jablons, and J. Benhattar, Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets, 2007. 11(3): p. 375-89. DOI: 10.1517/14728222.11.3.375.
106. Yuan, X., H. Wu, H. Xu, H. Xiong, Q. Chu, S. Yu, G.S. Wu, and K. Wu, Notch signaling: An emerging therapeutic target for cancer treatment. Cancer Lett, 2015. DOI: 10.1016/j.canlet.2015.07.048.
107. Alketbi, A. and S. Attoub, Notch Signaling in Cancer: Ratio-nale and Strategies for Targeting. Curr Cancer Drug Targets, 2015. 15(5): p. 364-74. DOI: 10.2174/156800961505150710113353.
108. Schott, A.F., M.D. Landis, G. Dontu, K.A. Griffith, R.M. Lay-man, I. Krop, L.A. Paskett, H. Wong, L.E. Dobrolecki, M.T. Lewis, A.M. Froehlich, J. Paranilam, D.F. Hayes, M.S. Wicha, and J.C. Chang, Preclinical and clinical studies of gamma secretase inhibi-tors with docetaxel on human breast tumors. Clin Cancer Res, 2013. 19(6): p. 1512-24. DOI: 10.1158/1078-0432.CCR-11-3326.
109. De Jesus-Acosta, A., D. Laheru, A. Maitra, J. Arcaroli, M.A. Rudek, A. Dasari, P.J. Blatchford, K. Quackenbush, and W. Messer-smith, A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocar-cinoma. Invest New Drugs, 2014. 32(4): p. 739-45. DOI: 10.1007/s10637-014-0083-8.
110. Strosberg, J.R., T. Yeatman, J. Weber, D. Coppola, M.J. Schell, G. Han, K. Almhanna, R. Kim, T. Valone, H. Jump, and D. Sullivan, A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer, 2012. 48(7): p. 997-1003. DOI: 10.1016/j.ejca.2012.02.056.
111. Li, Y., Ahmad, A., Sarkar and F. H., ASPP and iASPP: Impli-cation in cancer development and progression. Cell. Mol. Biol. 2015, 61(6): 2-8.
112. Masood, N., Qureshi, M. Z. and Yasmin, A., Association of NOTCH with different microRNAs in head and neck cancer. Cell. Mol. Biol. 2015, 61(6): 9-16.
113. Amirkhah, R., Farazmand, A., Irfan-Maqsood, M., Wolken-hauerand, O. and Schmitz, U., The role of microRNAs in the resis-tance to colorectal cancer treatments. Cell. Mol. Biol. 2015, 61(6): 17-23.
114. Limami, Y., Pinon, A., Riaz, A. and Simon, A., TRAIL and targeting cancer cells: between promises and obstacles. Cell. Mol. Biol. 2015, 61(6): 33-38.
115. Silva Galbiatti-Dias, A. L., Pavarino, É. C., Kawasaki-Oyama, R. S., Maniglia, J. V., Maniglia, E. J. V. and Goloni Bertollo, E. M., Cancer stem cells in head and neck cancer: A Mini Review. Cell. Mol. Biol. 2015, 61(6): 39-43.
116. Musella, A., Marchetti, C., Gasparri, M. L., Salerno, L., Caso-relli, A., Domenici, L., Imperiale, L., Ruscito, I., Abdul Halim, T., Palaia, I., Di rDonato, V., Pecorini, F., Monti, M., Muzii, L. and Pani-ci, P. B., PARP inhibition: A promising therapeutic target in ovarian cancer. Cell. Mol. Biol. 2015, 61(6): 44-61.
117. Attar, R., Tabassum, S., Fayyaz, S., Ahmad, M. S., Nogueira, D. R., Yaylim, I., Timirci-Kahraman, O., Kucukhuseyin, O., Cacina, C., Farooqi, A. A. and Ismail, M., Natural products are the future of anticancer therapy: Preclinical and clinical advancements of Viscum album phytometabolites. Cell. Mol. Biol. 2015, 61(6): 62-68.
118. Hsu, Y-C., Hsieh, Y-H., Liao, C-C., Chong, L-W., Lee, C-Y., Yu, Y-L. and Chou, R-H., Targeting post-translational modifications of histones for cancer therapy. Cell. Mol. Biol. 2015, 61(6): 69-84.
119. Chong, L-W., Chou, R-H., Liao, C-C., Lee, T-F., Lin, Y., Yang, K-C. and Hsu, Y-C. Saturated fatty acid induces cancer stem cell-like properties in human hepatoma cells. Cell. Mol. Biol. 2015, 61(6): 85-91.
120. Smina, T. P., Mohan, A., Ayyappa, K. A., Sethuraman, S. and Krishnan, U. M., Hesperetin exerts apoptotic effect on A431 skin carcinoma cells by regulating mitogen activated protein kinases and cyclins. Cell. Mol. Biol. 2015, 61(6): 92-99.
121. Ahmadi, M., Jafari, R., Marashi, S. A. and Farazmand, A., In-direct role of microRNAs and transcription factors in the regulation of important cancer genes: A network biology approach. Cell. Mol. Biol. 2015, 61(6): 100-107.
122. Zahoor, A., Mansoor, Q., Farooqi, A. A., Fayyaz, S., Naz, G. and Ismail, M., Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4) genes contribute to susceptibility to colorectal cancer in pakistani popula-tion. Cell. Mol. Biol. 2015, 61(6): 108-112.